Mark Joy, Utkarsh Agrawal, Xuejuan Fan, Chris Robertson, Sneha N Anand, Jose Ordonez-Mena, Rachel Byford, Rosalind Goudie, Gavin Jamie, Debasish Kar, John Williams, Gemma L Marsden, Victoria Tzortziou-Brown, Sir Aziz Sheikh, F D Richard Hobbs, Simon de Lusignan
BACKGROUND: Thrombosis associated with thrombocytopenia was a matter of concern post first and second doses of BNT162b2 and ChAdOx1 COVID-19 vaccines. Therefore, it is important to investigate the risk of thrombocytopenic, thromboembolic and haemorrhagic events following a second dose of BNT162b2 and ChAdOx1 COVID-19 vaccines. METHODS: We conducted a large-scale self-controlled case series analysis, using routine primary care data linked to hospital data, among 12...
September 2023: The Lancet regional health. Europe